Overview

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Status:
RECRUITING
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
Crizotinib
ensartinib
larotrectinib
pralsetinib
pyrotinib